1. Home
  2. NNVC vs PASG Comparison

NNVC vs PASG Comparison

Compare NNVC & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NNVC
  • PASG
  • Stock Information
  • Founded
  • NNVC 2005
  • PASG 2017
  • Country
  • NNVC United States
  • PASG United States
  • Employees
  • NNVC N/A
  • PASG N/A
  • Industry
  • NNVC Biotechnology: Pharmaceutical Preparations
  • PASG Biotechnology: Pharmaceutical Preparations
  • Sector
  • NNVC Health Care
  • PASG Health Care
  • Exchange
  • NNVC Nasdaq
  • PASG Nasdaq
  • Market Cap
  • NNVC 23.1M
  • PASG 25.9M
  • IPO Year
  • NNVC N/A
  • PASG 2020
  • Fundamental
  • Price
  • NNVC $1.42
  • PASG $7.91
  • Analyst Decision
  • NNVC
  • PASG Strong Buy
  • Analyst Count
  • NNVC 0
  • PASG 4
  • Target Price
  • NNVC N/A
  • PASG $59.25
  • AVG Volume (30 Days)
  • NNVC 120.2K
  • PASG 39.8K
  • Earning Date
  • NNVC 11-13-2025
  • PASG 11-12-2025
  • Dividend Yield
  • NNVC N/A
  • PASG N/A
  • EPS Growth
  • NNVC N/A
  • PASG N/A
  • EPS
  • NNVC N/A
  • PASG N/A
  • Revenue
  • NNVC N/A
  • PASG N/A
  • Revenue This Year
  • NNVC N/A
  • PASG N/A
  • Revenue Next Year
  • NNVC $133.33
  • PASG N/A
  • P/E Ratio
  • NNVC N/A
  • PASG N/A
  • Revenue Growth
  • NNVC N/A
  • PASG N/A
  • 52 Week Low
  • NNVC $0.94
  • PASG $5.12
  • 52 Week High
  • NNVC $1.92
  • PASG $26.60
  • Technical
  • Relative Strength Index (RSI)
  • NNVC 47.13
  • PASG 61.62
  • Support Level
  • NNVC $1.36
  • PASG $7.93
  • Resistance Level
  • NNVC $1.46
  • PASG $8.20
  • Average True Range (ATR)
  • NNVC 0.05
  • PASG 0.40
  • MACD
  • NNVC 0.00
  • PASG -0.01
  • Stochastic Oscillator
  • NNVC 47.01
  • PASG 56.08

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

About PASG Passage Bio Inc.

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Share on Social Networks: